930-85-8

Basic information

• Product Name: 3-Amino-4-iodo-5-methylisoxazole
• Synonyms: 3-Amino-4-iodo-5-methylisoxazole;4-Iodo-5-methylisoxazol-3-amine;4-Iodo-5-methylisoxazol-3-amine, 4-Iodo-5-methyl-1,2-oxazol-3-amine
• CAS NO: 930-85-8
• Molecular Formula: C₄H₅IN₂O
• Molecular Weight: 223.99977
• Mol File: 930-85-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 104.0-104.5℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Amino-4-iodo-5-methylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-4-iodo-5-methylisoxazole(930-85-8)
• EPA Substance Registry System: 3-Amino-4-iodo-5-methylisoxazole(930-85-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 930-85-8(Hazardous Substances Data)

Usage

General Description

3-Amino-4-iodo-5-methylisoxazole is a chemical compound with the molecular formula C5H6IN3O. It is a heterocyclic organic compound containing an isoxazole ring with an amino, iodine, and methyl substituents. 3-Amino-4-iodo-5-methylisoxazole is used as a building block in organic synthesis and pharmaceutical research. It can be utilized in the preparation of various pharmaceutical compounds and agrochemicals. Due to its unique structure and reactivity, 3-Amino-4-iodo-5-methylisoxazole has potential applications in the development of new drugs and bioactive molecules. Additionally, it is important to note that this compound should be handled with care and proper safety precautions due to its potential hazards.

Upstream product

• 1072-67-9 5-methylisoxazol-3-ylamine 

Downstream Products

• 6455-42-1 N-(4-iodo-5-methyl-isoxazol-3-yl)-benzamide 
• 6455-26-1 N,N'-bis-(4-iodo-5-methyl-isoxazol-3-yl)-4,4'-diazenediyl-bis-benzenesulfonamide 
• 6455-25-0 6,13-bis-(4-iodo-5-methyl-isoxazol-3-yl)-5,7,12,14-tetrathia-2,3,6,9,10,13-hexaaza-1,4,8,11(1,4)-tetrabenzena-cyclotetradecaphane-2,9-diene 5,5,7,7,12,12,14,14-octaoxide 
• 6455-23-8 (4-iodo-5-methyl-isoxazol-3-yl)-bis-(toluene-4-sulfonyl)-amine 
• 6455-24-9 N-(4-iodo-5-methyl-isoxazol-3-yl)-toluene-4-sulfonamide 
• 6453-54-9 (4-iodo-5-methyl-isoxazol-3-yl)-bis-(4-nitro-benzenesulfonyl)-amine 
• 6453-55-0 N-(4-iodo-5-methyl-isoxazol-3-yl)-4-nitro-benzenesulfonamide 

Relevant articles and documents

Energetic and topological approach for characterization of supramolecular clusters in organic crystals

In this work, an approach is proposed for understanding the crystal arrangements of organic compounds. The crystals are studied taking into account the stabilization energy and the topological properties like contact surfaces of a molecule (M1) due to the presence of neighboring Mn (cluster). The molecular system models chosen were five heterocycles and one β-enaminone. The cluster of compounds had a Molecular Coordination Number (MCN) of 14, except for one compound that had an MCN of 16. Our study showed that intermolecular interactions can be divided into four main types: type I, with large energy values and a small contact surface; type II, involving a large value for both the energy and the contact surface; type III, with small and medium energy values, and a medium-sized contact surface; and type IV, with small energy values and a relatively large contact surface. Additionally, from this approach we show that only from the supramolecular cluster is it possible to observe the participation of the topological component during the formation of the crystal. This is demonstrated by the fact that the fragility of the electrostatic interaction between M1 and one Mn in the same plane is compensated by a strong interaction of M1 with a molecule in another plane.

N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin

N-(4-halo-isoxazolyl)sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(4-halo-3-isoxazolyl)sulfonamides and N-(4-halo-5-isoxazolyl)benzenesulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.